FAAH Inhibitor Improves Function of Inflamed Bladders by Modulation of Anandamide and Palmitoylethanolamide

Introduction: We aim to study the effect of fatty acid amide hydrolase (FAAH) blockade on bladder hyperactivity and on fatty acid amides levels during cystitis. Material and Methods: Cystitis was induced in female Wistar rats using 5 mg/mL lipopolysaccharide (LPS). Control group were intravesical instilled with saline. LPS and control groups received intravenously (caudal vein) during cystometry: URB 937 (URB; FAAH antagonist) in doses of 0.007, 0.07, 0.7 and 7 mg/kg (cumulative, with 10 minutes interval). Using the maximal effective dose of URB (0.7 mg/kg, see below) animals received 10 uM MJ15 (CB1 receptor antagonist) or 0.3 mg SR144528 /kg (SR; CB2 receptor antagonist). At dose of 7 mg/kg, animals receive 1.4 μg SB366791/kg (SB; TRPV1 antagonist). Control and inflamed (without and with 0.7 and 7 mg/kg URB) group were euthanized and the bladder was harvested for the determination of anandamide (AEA) and palmitoylethanolamide (PEA) by mass spectrometry. Results: Frequency of control was not changed by URB treatment at any dose. LPS increase bladder frequency. 0.007 mg and 0.07 mg URB decrease bladder frequency of LPS-inflamed rats. 0.7 URB reversed LPS-induced bladder hyperactivity. At 7 mg, URB was unable to reverse or reduce LPS-induced bladder hyperactivity. The administration of CB1, CB2 and TRPV1 antagonists did not change the frequency of voiding contractions of naive animals. CB1 antagonist reversed the effect of 0.7 URB while TRPV1 antagonist reduced the effect of 7 URB. AEA levels increase during inflammation. Treating LPS-inflamed animals with 0.7 mg URB brought AEA levels to control levels. Treating LPS-inflamed animals with 7 mg URB did not change AEA levels, compared to LPS-inflamed animals. PEA levels decrease during inflammation. Treating LPS-inflamed animals with 0.7 mg URB brought AEA levels to control levels. Treating LPS-inflamed animals with 7 mg URB, decreased PEA levels to values similar to the ones observed in LPS- -inflamed animals. Conclusion: During cystitis, the FAAH inhibitor raises the levels of PEA and reverses the urinary frequency by a CB1 receptor- mediated mechanism. When used in very high doses, the FAAH antagonist raises the levels of AEA and increases the urinary frequency by a TRPV1-dependent mechanism. Therefore, the choice of FAAH inhibitor dosage to be used in the clinics should consider the putative effects over the endocannabinoid levels in the system.

[1]  R. Capasso,et al.  Protective effect of palmitoylethanolamide in a rat model of cystitis. , 2015, Journal of Urology.

[2]  C. Fowler.  Transport of endocannabinoids across the plasma membrane and within the cell , 2013, The FEBS journal.

[3]  B. Taylor.  N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia , 2013, PAIN®.

[4]  F. Guimarães,et al.  Effects of glutamate NMDA and TRPV1 receptor antagonists on the biphasic responses to anandamide injected into the dorsolateral periaqueductal grey of Wistar rats , 2013, Psychopharmacology.

[5]  T. Smart,et al.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.

[6]  G. Jay,et al.  Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. , 2012, British journal of clinical pharmacology.

[7]  F. Montorsi,et al.  Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. , 2012, European urology.

[8]  C. Hillard,et al.  Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation , 2011, BJU international.

[9]  Benjamin F. Cravatt,et al.  Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[10]  E. Dainese,et al.  Intracellular trafficking of anandamide: new concepts for signaling. , 2010, Trends in biochemical sciences.

[11]  D. Deutsch,et al.  Identification of intracellular carriers for the endocannabinoid anandamide , 2009, Proceedings of the National Academy of Sciences.

[12]  D. Barrett,et al.  ‘Entourage’ effects of N‐palmitoylethanolamide and N‐oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors , 2008, British journal of pharmacology.

[13]  Tanezumab takes on pain due to osteoarthritis of the knee , 2008 .

[14]  F. Cruz,et al.  Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. , 2007, The Journal of urology.

[15]  T. Mikkelsen,et al.  A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals* , 2006, Journal of Biological Chemistry.

[16]  S. Bevan,et al.  Anandamide-Evoked Activation of Vanilloid Receptor 1 Contributes to the Development of Bladder Hyperreflexia and Nociceptive Transmission to Spinal Dorsal Horn Neurons in Cystitis , 2004, The Journal of Neuroscience.

[17]  M. Murakami,et al.  Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. , 2004, The Biochemical journal.

[18]  C. Hillard,et al.  Cellular accumulation of anandamide: consensus and controversy , 2003, British journal of pharmacology.

[19]  L. Petrocellis,et al.  Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response , 2003, Cellular and Molecular Life Sciences CMLS.

[20]  K. Waku,et al.  Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[21]  L. Petrocellis,et al.  Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. , 2001, Archives of biochemistry and biophysics.

[22]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Fowler,et al.  Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen , 2001, British journal of pharmacology.

[24]  W. Farquhar-Smith,et al.  Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated with Inflammation of the Urinary Bladder , 2001, Anesthesiology.

[25]  R. Pertwee,et al.  Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder , 1996, British journal of pharmacology.